MDx Firm Provista Dx Raises $6M in Series B Financing | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Provista Diagnostics today announced the completion of a Series B financing round that raised $6 million.

Existing investors participated in the round, which will be used to expand the company's commercial market development of dtectDx-Breast as Provista pursues 510(k) clearance of the assay. The firm also plans to conduct additional clinical trials for the test, which detects blood-based protein biomarkers that are "highly associated" with the development of breast cancer, it said on its website.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.